Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $2.8 million.

  • Ocular Therapeutix's Capital Expenditures rose 130544.55% to $2.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $12.0 million, marking a year-over-year increase of 83245.34%. This contributed to the annual value of $12.0 million for FY2025, which is 83245.34% up from last year.
  • Ocular Therapeutix's Capital Expenditures amounted to $2.8 million in Q4 2025, which was up 130544.55% from $6.0 million recorded in Q3 2025.
  • In the past 5 years, Ocular Therapeutix's Capital Expenditures registered a high of $6.0 million during Q3 2025, and its lowest value of $89000.0 during Q3 2024.
  • Over the past 5 years, Ocular Therapeutix's median Capital Expenditures value was $550000.0 (recorded in 2022), while the average stood at $1.2 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first tumbled by 8839.89% in 2024, then skyrocketed by 663370.79% in 2025.
  • Quarter analysis of 5 years shows Ocular Therapeutix's Capital Expenditures stood at $631000.0 in 2021, then soared by 240.73% to $2.2 million in 2022, then plummeted by 78.65% to $459000.0 in 2023, then tumbled by 55.99% to $202000.0 in 2024, then surged by 1305.45% to $2.8 million in 2025.
  • Its Capital Expenditures was $2.8 million in Q4 2025, compared to $6.0 million in Q3 2025 and $1.2 million in Q2 2025.